Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy
Current Issues in Molecular Biology · 08.07.2025 · 47 (7) · 525
DOI: 10.3390/cimb47070525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 08.07.2025. Verfasst von Laura Denisa Dragu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, and The Romanian Academy, The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, The Romanian Academy.
Abstract (Originalsprache)
This manuscript assesses the critical role of exosomal PD-L1 (ExoPD-L1) in immune suppression, tumor progression, and resistance to therapy. ExoPD-L1 has been identified as a key mediator of tumor immune evasion, contributing to systemic immunosuppression beyond the tumor microenvironment (TME) due to its capacity to travel to distant anatomical sites. In this context, the review aims to elaborate on the mechanisms by which exosomal PD-L1 interacts with T cell receptors and modulates both the tumor microenvironment and immune responses, impacting patient outcomes. We further explore emerging therapeutic strategies that target ExoPD-L1 to enhance the effectiveness of immunotherapy. Blocking ExoPD-L1 offers a novel approach to counteracting immune escape in cancer. Promising strategies include inhibiting exosome biogenesis with GW4869 or Rab inhibitors, neutralizing ExoPD-L1 with targeted antibodies, and silencing PD-L1 expression through RNA interference (RNAi) or CRISPR-based methods. While each approach presents certain limitations, their integration into combination therapies holds significant potential to improve the efficacy of immune checkpoint inhibitors. Future research should focus on optimizing these strategies for clinical application, with particular attention to improving delivery specificity and minimizing off-target effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
- Faculty of Medicine, Titu Maiorescu University, 040051 Bucharest, Romania.
ORCID-Profile: Laura Denisa Dragu, Mihaela Chivu-Economescu, Ioana Madalina Pitica, Lilia Matei, Coralia Bleotu, Carmen Cristina Diaconu
Förderung
- The Ministry of Investments and European Projects, through the Managing Authority for the Health Program, and The Romanian Academy
- The Ministry of Investments and European Projects, through the Managing Authority for the Health Program
- The Romanian Academy
Zitieren
APA
Dragu, L. D., Chivu-Economescu, M., Pitica, I. M., Matei, L., Bleotu, C., Diaconu, C. C., & Necula, L. G. (2025). Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy. Current Issues in Molecular Biology, 47(7), 525. https://doi.org/10.3390/cimb47070525
Vancouver
Dragu LD, Chivu-Economescu M, Pitica IM, Matei L, Bleotu C, Diaconu CC, et al. Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy. Current Issues in Molecular Biology. 2025;47(7):525. doi:10.3390/cimb47070525
BibTeX
@article{Dragu2025,
author = {Dragu, Laura Denisa and Chivu-Economescu, Mihaela and Pitica, Ioana Madalina and Matei, Lilia and Bleotu, Coralia and Diaconu, Carmen Cristina and Necula, Laura Georgiana},
title = {Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy},
journal = {Current Issues in Molecular Biology},
year = {2025},
volume = {47},
number = {7},
pages = {525},
doi = {10.3390/cimb47070525}
}
EUVIMED